Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors
20 Setembro 2022 - 9:00AM
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the
“Company”), a biotechnology company focused on the discovery,
research and development of new and effective treatments for
central nervous system (“CNS”) disorders, today announced that
Alfred J. Novak was appointed to its Board of Directors (the
“Board”). Mr. Novak replaces Dr. Yassine Bendiabdallah, who stepped
down from the Board on September 14, 2022.
Mr. Novak has broad operating experience as a
Chief Executive Officer and Chief Financial Officer and has served
on the boards of several pharmaceutical and medical device
companies. Mr. Novak brings financial acumen and extensive
expertise in product development, regulatory approval, commercial
activities, and a track record of delivering substantial value for
stockholders. Mr. Novak served as a director of Dova
Pharmaceuticals, which was sold to Swedish Orphan Biovitrum AB or
Sobi™, a company focused on rare diseases, for over $900 million; a
director and CEO of Biosense, which was sold to Johnson &
Johnson for $400 million; and CFO of Cordis Corporation, which was
acquired by Johnson & Johnson for $1.8 billion. He received his
MBA from the Wharton School of the University of Pennsylvania with
a concentration in Healthcare Administration and a BS from the
United States Merchant Marine Academy.
Professor Lawrence Steinman, Chairman of the
Board of Pasithea, stated, “We are pleased to welcome Mr. Novak to
our Board of Directors. We are thrilled that an individual of Al’s
caliber has joined Pasithea’s Board and his input will be
invaluable as we continue our progress toward developing
proprietary drug candidates and achieve value-creating milestones.
The Board would like to express its appreciation to Dr.
Bendiabdallah for all his dedication and contributions to
Pasithea.”
Mr. Novak commented, “Pasithea is an exciting
company with a promising portfolio of assets, encouraging
pre-clinical results for its lead drug candidates and a world
recognized team of scientists. I am honored to join Pasithea’s
Board and will work with my fellow directors and the management
team to develop novel and groundbreaking therapies to improve
patients’ lives and create shareholder value.”
About Pasithea Therapeutics Corp.
Pasithea Therapeutics Corporation is a
biotechnology company focused on the discovery, research and
development of new and effective treatments for central nervous
system (CNS) disorders. With an experienced team of experts in the
fields of neuroscience and psychopharmacology, Pasithea is
developing new molecular entities for the treatment of psychiatric
and neurological disorders, including Amyotrophic Lateral Sclerosis
(ALS) and Multiple Sclerosis (MS). Pasithea addresses the needs of
patients currently suffering with mental illness by providing
access to IV ketamine infusions both in clinics and in-home
settings.
Forward Looking Statements
This press release contains statements that
constitute “forward-looking statements.” Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to the Company on the date of this
release. These forward-looking statements are based upon current
estimates and assumptions and are subject to various risks and
uncertainties, including, without limitation, those set forth in
the Company’s filings with the SEC. Thus, actual results could be
materially different. The Company undertakes no obligation to
update these statements whether as a result of new information,
future events or otherwise, after the date of this release, except
as required by law. Such forward-looking statements are subject to
risks (including those set forth in the Company’s Form 10-K for the
fiscal year ended December 31, 2021, as amended, filed with the
U.S. Securities and Exchange Commission) and uncertainties which
could cause actual results to differ from the forward-looking
statements.
Pasithea Therapeutics Corp. Company Contact
Dr. Tiago Reis MarquesChief Executive OfficerE:
tiago@pasithea.com
Pasithea Therapeutics Corp. Investor
Relations
Lisa M. WilsonIn-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
Pasithea Therapeutics Corp. Media Contact
Caitlin KasunichKCSAE: ckasunich@kcsa.com
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Pasithea Therapeutics (NASDAQ:KTTAW)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024